Mana.bio , a biotechnology company pioneering work at the intersection of artificial intelligence and RNA delivery , announced the launch of Mina™, the world's first large-scale language model ( LLM ) specifically designed for lipid nanoparticles ( LNPsChatGPT for LNPs "—is available to the public at no cost and represents a significant advance in accelerating scientific discovery and advancing gene therapy and RNA-based medicines.

"AI has transformed many industries, but biology is just beginning to realize its full potential," said Yogev Debi , co-founder and CEO of Mana.bio. "At Mana, we've already achieved breakthroughs in RNA delivery using AI, demonstrating how it can unlock entirely new scientific possibilities. With the launch of Mina, we're not just introducing a new tool—we're opening a new chapter in science. We envision a future where AI-driven platforms accelerate discoveries, bridge the gap between the bench and the bedside, and ultimately improve people's health."

Mina represents a groundbreaking tool for scientists working in RNA delivery and therapeutics development. By providing access to curated data, predictive models, and optimized drug formulation insights, Mina accelerates the pace of research, reduces barriers to innovation, and enables researchers to develop new therapies with greater precision and confidence.

Mina, accessible at mina.mana.bio , is available to researchers and scientists worldwide and offers selected features to support experiments, data analysis, and LNP design. Specifically, Mina offers:

• Predictive modeling: Predicting critical LNP properties such as particle size, allowing researchers to optimize formulations early in the development process.
  
  
• Curated data retrieval: Provides access to normalized, high-quality data from trusted, public scientific sources, ensuring accuracy and reliability.
  
  
• Formulation Optimization: Provides guidance on key performance factors such as stability, tropism, and safety to accelerate the path from concept to clinical use.
  
  
• Exploring public data: Enables the discovery of patterns and trends in existing LNP research to foster innovation.

While Mana.bio maintains exclusive access to its most advanced predictive models and proprietary datasets, the company is eager to collaborate with partners interested in leveraging Mina's full platform capabilities.